MobiHealth News January 24, 2024
The company’s diagnostics platform helps predict how patients will respond to immunotherapy.
Elephas, an oncology-focused diagnostics platform, announced it secured $55 million in Series C funding, bringing its total raise to $116.5 million.
Venture Investors Health Fund and the State of Wisconsin Investment Board (SWIB) led the round.
Existing investors Northpond Ventures, Moore Strategic Ventures, WARF Ventures, Tao Invest, Sands Capital and ARCH Ventures also participated in the raise.
WHAT IT DOES
Elephas is developing a diagnostics platform to predict a patient’s response to immunotherapy using metabolic imaging.
Immunotherapy is a therapeutic approach that helps the immune system fight cancer.
The Wisconsin-based company analyzes a tumor’s architecture via a patient biopsy and treats it with...
Today's Sponsors
Today's Sponsor